Article
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
Pharmacogenetics and genomics - 1 Mar 2013
Ellsworth Katarzyna A, Moon Irene, Eckloff Bruce W, Fridley Brooke L, Jenkins Gregory D, Batzler Anthony, Biernacka Joanna M, Abo Ryan, Brisbin Abra, Ji Yuan, Hebbring Scott, Wieben Eric D, Mrazek David A, Weinshilboum Richard M, Wang Liewei
Abstract excerpt
OBJECTIVES: FKBP51 (51 kDa immunophilin) acts as a modulator of the glucocorticoid receptor and a negative regulator of the Akt pathway. Genetic variation in FKBP5 plays a role in antidepressant response. The aim of this study was to comprehensively assess the role of genetic variation in FKBP5, identified by both Sanger and Next Generation DNA resequencing, as well as genome-wide single nucleotide polymorphisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
